FDA published a draft guidance of recommendations for biosimilar product labeling.
On the evening of Nov. 12, President Donald Trump signed a continuing resolution that officially ended the 43-day-long U.S. government shutdown that began on Oct. 1.
FDA Publishes Draft Guidance On Biosimilar Product Labeling
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.
CMS announced a new drug payment model called the GENErating cost Reductions for U.S. Medicaid (GENEROUS) Model that the agency plans to pilot next year.
Christine M. Lovly will spearhead the development of City of Hope’s new national thoracic oncology program, effective Jan. 1, 2026.
Thomas George, a gastrointestinal medical oncologist and expert in clinical research, has been named interim director of the University of Florida Health Cancer Institute, effective Nov. 17.
Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of the University of Texas at San Antonio, have been awarded three multi-year grants totaling $6 million from NIH to address treatment and pain management for oral cancer.
